Axsome Therapeutics Reports $260 Million in Q3 Revenue and Projects AUVELITY Peak Sales of $8 Billion
Axsome Therapeutics (AXSM) reported a robust third quarter, generating $260 million in total revenue. The company's growth is being driven by strong commercial progress within its neuroscience portfolio, specifically the continued performance of its product AUVELITY. Management has issued optimistic long-term guidance, projecting that AUVELITY will reach peak annual revenues of at least $8 billion. Additionally, the company is advancing its pipeline, with AXS-12 approaching a critical PDUFA date scheduled for May 1, 2027.
Tickers: $AXSM
Topics: neuroscience pipeline quarterly earnings revenue growth